Subjective experience of the environment determines serotoninergic antidepressant treatment outcome in male mice

J Affect Disord. 2024 Apr 1:350:900-908. doi: 10.1016/j.jad.2024.01.145. Epub 2024 Jan 19.

Abstract

Background: The effects of the selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressant treatment, have been proposed to be affected, at least in part, by the living environment. Since the quality of the environment depends not only on its objective features, but also on the subjective experience, we hypothesized that the latter plays a key role in determining SSRI treatment outcome.

Methods: We chronically administered the SSRI fluoxetine to two groups of adult CD-1 male mice that reportedly show distinct subjective experiences of the environment measured as consistent and significantly different responses to the same emotional and social stimuli. These distinct socioemotional profiles were generated by rearing mice either in standard laboratory conditions (SN) or in a communal nest (CN) where three dams breed together their offspring, sharing caregiving behavior.

Results: At adulthood, CN mice displayed higher levels of agonistic and anxiety-like behaviors than SN mice, indicating that they experience the environment as more socially challenging and potentially dangerous. We then administered fluoxetine, which increased offensive and anxious response in SN, while producing opposite effects in CN mice. BDNF regulation was modified by the treatment accordingly.

Limitations: Subjective experience in mice was assessed as behavioral response to the environment.

Conclusions: These results show that the subjective experience of the environment determines fluoxetine outcome. In a translational perspective, our findings suggest considering not only the objective quality, but also the subjective appraisal, of the patient's living environment for developing effective personalized therapeutic approaches in psychiatry.

Keywords: BDNF; Context; Individuality; Major depressive disorder; Plasticity; Selective serotonin reuptake inhibitors.

MeSH terms

  • Adult
  • Animals
  • Antidepressive Agents* / pharmacology
  • Antidepressive Agents* / therapeutic use
  • Anxiety
  • Fluoxetine* / pharmacology
  • Fluoxetine* / therapeutic use
  • Humans
  • Male
  • Mice
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Fluoxetine
  • Antidepressive Agents
  • Selective Serotonin Reuptake Inhibitors